Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | NAAA | Q02083 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | HPGD | P15428 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 2/20 | 0.45 |
| ▸ | ADH1B | P00325 | 2/20 | 0.45 |
| ▸ | ADH1C | P00326 | 2/20 | 0.45 |
| ▸ | ADH1A | P07327 | 2/20 | 0.45 |
| ▸ | ADH7 | P40394 | 2/20 | 0.45 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.44 |
| ▸ | DGKA | P23743 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | ADH4 | P08319 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.42 |
| ▸ | PPARG | P37231 | 1/20 | 0.42 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.42 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.42 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7672094 | 0.94 | NAAA (0.57) | ATMNAAAFAAHADH1BADH1C | |
| SCHEMBL7004135 | 0.92 | NAAA (0.60) | NAAATSHRFAAHADH1BADH1C | |
| SCHEMBL1864795 | 0.92 | NAAA (0.60) | NAAATSHRFAAHADH1BADH1C | |
| SCHEMBL11677656 | 0.92 | NAAA (0.60) | NAAATSHRFAAHADH1BADH1C | |
| SCHEMBL5982054 | 0.92 | NAAA (0.60) | NAAATSHRFAAHADH1BADH1C | |
| SCHEMBL6948953 | 0.90 | NAAA (0.41) | ATMNAAAALDH1A1HPGDTSHR | |
| SCHEMBL8390838 | 0.85 | ALDH1A1 (0.54) | ATMNAAAALDH1A1HPGDTSHR | |
| SCHEMBL27703892 | 0.83 | ADH1B (0.50) | ATMNAAAALDH1A1HPGDTSHR | |
| SCHEMBL21578651 | 0.82 | ALDH1A1 (0.50) | ATMNAAAALDH1A1HPGDTSHR | |
| SCHEMBL17970767 | 0.82 | ALDH1A1 (0.50) | ATMNAAAALDH1A1HPGDTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 122 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101664553-B | Stabilization of hypoxia inducible factor (HIF) alpha | FIBROGEN INC | 2013-08-21 | — | — | CN | claimed |
| JP-2011527701-A | — | — | 2011-11-04 | — | — | JP | claimed |
| EP-2331503-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2011-06-15 | — | — | EP | claimed |
| WO-2010006191-A1 | 4-PHENOXYMETHYLPIPERIDINES AS MODULATORS OF GPR119 ACTIVITY | IRM LLC (BM) | 2010-01-14 | — | — | WO | claimed |
| EP-1189891-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION Bioscience AG (DE) | 2002-03-27 | — | — | EP | claimed |
| US-6362342-B1 | BIOSYNTHESIS; DRUG LIBRARIES | LION BIOSCIENCE AG (DE) | 2002-03-26 | — | — | US | claimed |
| WO-2001000594-A1 | TRIAZOLE COMPOUNDS AND COMBINATORIAL LIBRARIES THEREOF | LION BIOSCIENCE AG (DE) | 2001-01-04 | — | — | WO | claimed |
| WO-2021127461-A1 | METHODS OF SYNTHESIZING 4-VALYLOXYBUTYRIC ACID | XW LABORATORIES LIMITED (CN) | 2021-06-24 | — | — | WO | disclosed |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-06-16 | — | — | US | disclosed |
| EP-2939668-A1 | PDK4 INHIBITOR AND USE THEREOF | The Kitasato Institute (JP) | 2015-11-04 | — | — | EP | disclosed |
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-07-23 | — | — | US | disclosed |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-02-19 | — | — | US | disclosed |
| US-8901171-B2 | Compounds for suppressing a peripheral nerve disorder induced by an anti-cancer agent | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-0436902-A1 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-07-17 | — | — | EP | disclosed |
| US-4983609-A | Anticancer agents | OTSUKA PHARMACEUTICAL (JP) | 1991-01-08 | — | — | US | disclosed |
| US-4864021-A | ANTICARCINOGENIC AGENTS, ANTITUMOR AGENTS | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-09-05 | — | — | US | disclosed |
| EP-0323441-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1989-07-05 | — | — | EP | disclosed |
| EP-0247381-A2 | 5-flurorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-12-02 | — | — | EP | disclosed |
| EP-0180897-A2 | 5-Fluorouracil derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-14 | — | — | EP | disclosed |
| EP-0180188-A2 | A composition for increasing the anti-cancer activity of an anti-cancer compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1986-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203464-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ATM 2903/4885NAAA 195/4885ALDH1A1 2141/4885 |
| US-20160166526-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ATM 2903/4885NAAA 195/4885ALDH1A1 2141/4885 |
| US-20150051256-A1 | COMPOUNDS FOR SUPPRESSING A PERIPHERAL NERVE DISORDER INDUCED BY AN ANTI-CANCER AGENT | PMP22, GAP43, NGF | ATM 2903/4885NAAA 195/4885ALDH1A1 2141/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.